TP53 and prostate carcinoma: The drug-induced impediment of the MDM2-p53 interaction increased p53 levels, leading to the upregulation of p53 target genes and wt-p53-dependent induction of apoptosis in several human breast, colon and prostate cancer cell lines [105].